Zoetis Inc. $ZTS Shares Sold by Sax Wealth Advisors LLC

Sax Wealth Advisors LLC cut its holdings in Zoetis Inc. (NYSE:ZTS) by 10.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,511 shares of the company’s stock after selling 410 shares during the quarter. Sax Wealth Advisors LLC’s holdings in Zoetis were worth $548,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of ZTS. Lindbrook Capital LLC boosted its holdings in shares of Zoetis by 1.8% in the 1st quarter. Lindbrook Capital LLC now owns 3,715 shares of the company’s stock valued at $612,000 after buying an additional 65 shares during the period. Scott & Selber Inc. boosted its holdings in shares of Zoetis by 0.6% in the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock valued at $1,817,000 after buying an additional 67 shares during the period. Secure Asset Management LLC lifted its position in Zoetis by 2.9% in the 2nd quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock valued at $382,000 after purchasing an additional 68 shares during the last quarter. Quotient Wealth Partners LLC boosted its stake in Zoetis by 2.3% during the 1st quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company’s stock valued at $521,000 after purchasing an additional 72 shares during the period. Finally, Menard Financial Group LLC boosted its stake in Zoetis by 3.8% during the 1st quarter. Menard Financial Group LLC now owns 2,032 shares of the company’s stock valued at $305,000 after purchasing an additional 75 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Up 0.6%

Zoetis stock opened at $143.61 on Thursday. The firm has a market cap of $63.65 billion, a price-to-earnings ratio of 24.72, a price-to-earnings-growth ratio of 2.29 and a beta of 0.90. Zoetis Inc. has a 1 year low of $139.34 and a 1 year high of $196.55. The firm’s 50 day moving average price is $149.41 and its two-hundred day moving average price is $154.74. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday. Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and reduced their target price for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Argus reissued a “buy” rating and set a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Finally, Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Zoetis presently has an average rating of “Moderate Buy” and an average target price of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.